Equity Profile

IONS

Ionis Pharmaceuticals, Inc.

Health CareBiotechnology$8.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and is a key indicator for investors.

-0.91

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

187M

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases. Operating in the health care sector, Ionis specializes in RNA-targeted drug discovery and development, making it significant in the evolving landscape of genetic medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1 2026, Ionis reported an EPS of -0.56, which was better than the expected -0.89, resulting in a positive stock reaction of 4.25% the following day. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Ionis to report a loss of $0.91 per share on revenues of $187 million for Q2 2026. The market is closely watching for any signs of improved financial performance or updates on drug development.

Bull Case

If Ionis can exceed the EPS estimate and show strong revenue growth, it may indicate successful drug development and increased market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its drug pipeline, it could lead to a significant decline in stock value.

Key Metrics to Watch

EPS

-0.91

Earnings per share is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

187M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Ionis report an EPS better than the expected -0.91?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What guidance or updates will Ionis provide regarding its drug pipeline?

Investors will be keen to understand the progress of key drugs in development, as this can significantly impact future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Ionis to exceed EPS expectations due to recent positive trends in drug development.

Supporting Evidence

Ionis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent advancements in their drug pipeline could lead to better-than-expected results.

Key Risk

If the company provides strong updates on its drug pipeline, it could significantly alter investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can maintain its momentum from the previous quarter's surprise performance.

Bull Confirmed If

An EPS of -0.65 or better, along with revenue exceeding $225 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than -1.06 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by about 1.92% on the day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of around 5.29%, reflecting market disappointment and concern over the company's future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drugs in development.
2Management's commentary on operational efficiency and cost management.
3Details on revenue growth drivers and market demand.
4Guidance for future quarters and any changes in strategy.
5Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

EPS

Earnings per share is crucial as it reflects the company's profitability and is a key indicator for investors.

-0.91

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

187M

Wall Street expectations, options signals, track record, and call prep available with Pro.

IONS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+52.29%

Avg Stock Reaction

+1.02%

Last Quarter Recap

In Q1 2026, Ionis reported an EPS of -0.56, which was better than the expected -0.89, resulting in a positive stock reaction of 4.25% the following day. However, revenue details were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Ionis can exceed the EPS estimate and show strong revenue growth, it may indicate successful drug development and increased market confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on its drug pipeline, it could lead to a significant decline in stock value.

Key Metrics to Watch

EPS

-0.91

Earnings per share is crucial as it reflects the company's profitability and is a key indicator for investors.

Revenue

187M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Ionis report an EPS better than the expected -0.91?

A better-than-expected EPS could signal improved operational efficiency and boost investor confidence.

What guidance or updates will Ionis provide regarding its drug pipeline?

Investors will be keen to understand the progress of key drugs in development, as this can significantly impact future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Ionis to exceed EPS expectations due to recent positive trends in drug development.

Supporting Evidence

Ionis has a strong track record of beating EPS estimates, with an 88% beat rate over the last eight quarters.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Recent advancements in their drug pipeline could lead to better-than-expected results.

Key Risk

If the company provides strong updates on its drug pipeline, it could significantly alter investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Ionis can maintain its momentum from the previous quarter's surprise performance.

Bull Confirmed If

An EPS of -0.65 or better, along with revenue exceeding $225 million, would confirm the bull case.

Bear Confirmed If

An EPS worse than -1.06 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.45%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±9.5% while IONS has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

23.1%

Calls (20K)P/C Ratio: 0.06Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ionis beats expectations, history suggests the stock could rise by about 1.92% on the day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further commentary from management.

Miss

A miss could lead to a decline of around 5.29%, reflecting market disappointment and concern over the company's future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of key drugs in development.
2Management's commentary on operational efficiency and cost management.
3Details on revenue growth drivers and market demand.
4Guidance for future quarters and any changes in strategy.
5Insights into competitive positioning within the biotechnology sector.